Connect with us

Cannabis News

Bipartisan Congressional Lawmakers Give Mixed Reactions To Marijuana Rescheduling News From Trump Administration

Published

8 months ago

on

Bipartisan congressional lawmakers are making a potentially immediate decision President Donald Trump to move forward with federal marijuana overhaul—Democrats like Rep. Alex Ocasio-Cortez (D-NY) call the reform a “no” and others like Rep. Andy Harris (R-MD) have pushed back against the proposal.

It was first reported on Thursday that Trump plans to sign an executive order on the reorganization, possibly directing the attorney general to complete the process started by the Biden administration to reclassify cannabis under Title III of the Controlled Substances Act (CSA).

Since then, several lawmakers from both sides of the aisle have weighed in on the plan in interviews with Marihuana Moment. While Democrats may disagree with the president on many policy issues, they have generally welcomed news of the restructuring’s development, though they would eventually like to see the federal ban end entirely rather than increase change.

Ocasio-Cortez said it was a “no brainer” to implement the policy change, which would legalize marijuana but remove some barriers to research and allow cannabis businesses to take a federal tax deduction, symbolically recognizing the plant’s medical value.

“I have honestly felt that it has been a race between the two major parties to get reform,” said the congressman. “I mean, it’s inevitable, so of course I’m all for that move.”

Asked about reports that House Speaker Mike Johnson (R-LA) told Trump not to reschedule, Ocasio-Cortez said an executive order would bypass lawmakers who oppose it. The speaker “has no pen” in such orders, he said.

“If he wants to try to pass some legislation and push his entire Republican team to do that, I think that’s within his power,” the congressman said.

Rep. Ilhan Omar (D-MN), co-chair of the Congressional Cannabis Caucus, told Marihuana Moment that while it’s true that Trump plans to advance rescheduling, that would be a “game changer” and a “huge” accomplishment.

However, he said that it is difficult for any member of parliament to take his word seriously, “because the president has often changed his position on various policy issues in the past. “I hope (he will act on the rescheduling) and it will come true,” he said.

Rep. Dina Titus (D-NV), another co-chair of the Congressional Cannabis Caucus, told Marijuana Moment that “Trump’s proposal would be a positive step toward cannabis policy reform, but more work remains.”

“While it would ease restrictions on medical cannabis research and alleviate some of the tax burden on state illegal cannabis businesses, classifying marijuana as a Schedule III substance still allows for the unfair and disproportionate incarceration of recreational users and limits access to banking services for cannabis businesses,” he said. “We must continue to address the systemic inequality associated with scheduling cannabis as a dangerous drug.”

House Majority Leader Steve Scalise (R-LA), for his part, did not weigh in on the merits of the reconsideration proposal, but told Marijuana Moment that he was with the president Thursday afternoon and “didn’t hear that” about plans to end the reform process.

One of the House’s most outspoken anti-marijuana lawmakers, Rep. Andy Harris (R-MD), insisted that he doesn’t “agree with everything the president does, and I don’t.” He also appears to question the veracity of recent reports about the imminence of a restructuring move, stating that he was told “for sure” it would happen on Thursday, which did not materialize.

There have been mixed reports on the timing of a possible reconsideration action, with some sources still hopeful it will happen on Friday, CNBC to report that the executive order would be issued on Monday of next week and as early as Axios to report that the reform is expected to come early next year.

Rep. Richard Hudson (R-NC), chairman of the National Republican Congressional Committee (NRCC), told Marihuana Moment that rescheduling is a “terrible idea” and noted that he had never discussed the issue with the House Speaker.

In a statement Friday, Sen. Kirsten Gillibrand (D-NY) said she was “encouraged to see the first move by the Drug Enforcement Administration under President Biden to reorganize marijuana, and I urge President Trump to continue that effort.”

“Common sense tells us that marijuana should not be in the same category as deadly drugs like heroin, and reclassifying it is a small step forward in creating economic opportunity, supporting research into the medical benefits of marijuana, and increasing public safety,” he said. “However, much more work remains to be done. I will continue to advocate for the complete decriminalization of marijuana and the expungement of the records of Americans convicted of marijuana possession.”

Rep. Ted Lieu (D-CA) reacted to the news by criticizing the Biden administration after it “failed” to complete marijuana rescheduling, and said he hopes the Trump administration doesn’t make the “same mistake.”

Meanwhile, Trump’s former White House press secretary, Sean Spicer, discussed the news development on an episode of his “The Huddle” podcast on Friday and said Trump’s potential reshuffle action, like other policy issues, “comes back to power and money.”

“There are a lot of people who instinctively think it’s a good play with young voters,” he said. “The bottom line, this whole reclassification, really comes down to the financial part of this.”

Spicer added that there is a “bank part” because cannabis companies have long faced a federal ban on accessing banking services, regardless of state laws. However, it inflated the impact of the reorganization on that issue, because placing marijuana in Schedule III of the CSA would not make it federally legal, so some banks would likely continue to avoid serving the marijuana industry even if this modest reform were enacted.

“It’s a big business with a lot of money, and I have to believe that’s what it really comes down to,” he said. “The president is not running for re-election … there are a lot of people who will not be happy about this. I am one of them.”




“You walk through downtown (Washington, DC) or any city, it smells like pot and piss,” he added. “I think, given where we are as a society, the last thing we need to do is make drugs more accessible. I don’t think it’s a good idea, but I’ll tell you, I think where people are missing the story is: Follow the money.”

Trump said this in mid-August he would make the reorganization decision in a week. But despite the growing timeline and rumors, a White House spokesperson told Marihuana Moments on Thursday that “no final decision has been made on rescheduling marijuana.”

The Washington Post reported Thursday afternoon that Trump planned to issue an executive order to federal agencies to move ahead with cannabis rescheduling.

The outlet also said the president met with marijuana industry executives Robert F. Kennedy Jr. earlier this week in the Oval Office. with Secretary of Health and Human Services and Centers for Medicare and Medicaid Services Administrator Mehmet Oz. During that meeting, Trump called Johnson, the House Speaker, who spoke out against the cannabis redistricting,

If the administration ultimately enacts the rescheduling, it would mark one of the most significant developments in federal marijuana policy since its prohibition half a century ago, when it was banned under Article III. With a reclassification, marijuana has medical value and a lower abuse potential compared to Schedule I drugs like heroin.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Trump endorsed the rescheduling — as well as an initiative to legalize access to industrial banking and adult use in Florida — on the campaign trail. The president had been silent on the issue since taking office for a second term, until a meeting in August where, in response to a reporter’s question, he announced that the administration would decide to reschedule in a few weeks.

The possibility of an immediate rescheduling announcement comes a few weeks later the president signed a major spending bill that would effectively ban most consumer hemp productsdrawing criticism from hemp industry players who say the policy change would wipe out the market.

LCB Contributed reporting from Washington DC

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Fluent to sell New York license and operations

Published

2 weeks ago

on

July 30, 2026

By











Fluent has entered into a definitive agreement to sell Etain, LLC, the Company’s New York-based operating entity. The purchase agreement was signed on July 22, 2026. The transaction provides for the sale of Etain’s Registered Entity license, certain of the Company’s New York operating assets and related New York leases for cash, subject to customary purchase price adjustments.

The Company believes the Transaction advances its strategic objectives and expects the Transaction to comply with applicable regulatory requirements in connection with the Company’s previously announced plan of arrangement for Vireo Growth Inc. (the “Deal”) while providing for an orderly transition of the New York operations to an experienced operator committed to serving patients and consumers.

Completion of the free transaction is subject to closing conditions, including, among other customary conditions, approval of the change in ownership by the New York State Cannabis Control Board and the completion of all conditions to the completion of the Agreement.

For more information:
FLUENT Corp
getfluent.com/










Continue Reading

Cannabis News

Marijuana Has ‘Horrific Health Risks’ And No Medical Value, Former Trump Attorney General Claims

Published

2 weeks ago

on

July 30, 2026

By

A former US attorney general who served in President Donald Trump’s first term says marijuana poses “tremendous health risks,” has no medical value and should not be rescheduled under federal law.

“Marijuana redistricting would create a false impression that it is safe, reduce penalties for illegally selling the drug, and provide a large tax windfall to those who legally supply it,” William Barr wrote in a Wednesday op-ed for The Washington Post, Kevin Sabet, CEO of the prohibitionist organization Smart Approaches to Marijuana. “That would be a disaster.”

The opinion comes as the Trump administration moves forward with cannabis reregulation.

According to an order issued in April by US Attorney General Todd Blanche, Marijuana products regulated by a state medical cannabis license were immediately changed from Schedule I As did marijuana products approved by the Food and Drug Administration (FDA) under Schedule III of the Controlled Substances Act (CSA).

an administrator The hearing is looking at the broader rescheduling of marijuanawith The Drug Enforcement Administration (DEA) has been tasked with advocating for cannabis reform highlighting the testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids. It included appearances by a Food and Drug Administration (FDA) scientist and a doctor from New Hampshire. Medical marijuana provides relief to pain patients and can serve as an alternative to opioids.

But Sabet and Barr, who served as Trump’s attorney general from 2019-2020, argued that “the evidence presented at the hearing did not support the rescheduling of marijuana” and instead “confirmed what decades of data have shown: raw marijuana has no scientifically established medical value and is highly susceptible to abuse.”

After the parties to the hearing have filed termination rights, the DEA administrative law judge overseeing the proceedings will make a recommendation regarding rescheduling, and the agency administrator will make a final decision.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling supporters that they do not meet the definition of “interested person” to participate because they have not been “affected or prejudiced by any rule or proposed rule that may be issued.”

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

The former attorney general’s new opinion says “the stakes couldn’t be higher”, arguing that “marijuana today is more dangerous than ever” and that it is “addictive”, throwing out a list of alleged harm to mental and physical health.

“These unhealthy effects are a predictable result of a powerful and addictive drug being normalized, commercialized and marketed as a medicine,” Barr and Sabet say. “It would be one thing if marijuana had medical value. But there is no credible evidence that marijuana is an effective treatment for any medical condition, despite the millions of dollars spent trying to prove otherwise.”

The Department of Health and Human Services (HHS) published a 252 analysis in 2023 that concluded that marijuana had accepted medical value and should be rescheduled.

The new opposition piece also says that “rescheduling would unlock enormous revenue for the corporate marijuana industry by bringing it into a category that has not been covered by a longstanding reduction in federal drug tax deductions,” referring to a law known as 280E, which repeals Sections I and II.

“This, in turn, would allow the industry to spend even more on advertising and marketing to young people,” Barr and Sabet. he wroteArguing that “those who would lose this dragon in society are laying the foundations for another Big Tobacco”.

The Sabet organization, SAM, is one of several parties Challenging the Marijuana Redistricting Process which have been upheld by a federal Court of Appeals. those separate parts State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

SAM’s lawsuit was signed by attorneys at Torridon Law PLLC, where Barr is a partner.

The team announced in January that it was Hiring Barr’s firm to fight cannabis rescheduling After Trump signed an executive order directing officials to quickly complete the process.

During the first Trump administration, Barr was accused by a Justice Department official Directing improper anti-company investigations into multiple cannabis company mergers– Accounting for almost a third of the division’s cases in 2019.

Several Democratic members of Congress introduced a resolution calling for an investigation into Barr’s possible impeachment, saying “abused the power of his office” to improperly investigate marijuana businesses while engaging in other allegedly illegal conduct.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

How much red light does cannabis really need?

Published

3 weeks ago

on

July 26, 2026

By

When growers pull out two LED fixtures side by side, the first number they usually discuss is percent red. This is an easy specification to fix. They are efficient at producing red photons and incredibly efficient at photosynthesis, and cannabis eats away at the flower. So more red must be better, right?

Not so simple. Red is an input to a spectrum, and the spectrum is an input to a room. There is no single spectrum that wins everywhere. An indoor room pushes hard, a greenhouse that soaks up sunlight, a temperamental cultivar, and aggressive yields call for something different. Knowing what each light strip actually does allows you to choose a tool that fits your grow instead of one that just has a big number on the sales page.

© JumpLights

Blue: structure
Blue (approximately 400-500 nm) gives shape to the plant. It maintains dense growth, strong stems, tight internodes and allows it to develop as desired. It also encourages stomatal opening, so the plant manages water and gas exchange better. Get blue and you’ve built a plant that can carry heavy flowers with no problem.

Green: access
Green was eliminated as the wavelength is “reflected” by plants. It turns out that it does a real job. Blue and red are absorbed above; the green goes deep into the fat and reaches the leaves that are never touched by the above photons. In a compact room, it’s the difference between plants photosynthesising from the top down and those that work only from the top. Green won’t replace your red or blue, but it does carry usable light where they can’t reach.

Red: engine
Red is the horse of the flower. It absorbs as efficiently as anything in the spectrum, and is responsible for most of the biomass you’re after. Redder generally means faster flower development, more weight and better efficiency per watt.

But red has a ceiling, and it’s tied to what you run. Push PPFD upwards with a heavy red spectrum and some cultivars begin to whiten at the top: the flower should be dense with pale, washed tips. Genetics, intensity, barrel temperature and your general environment all feed into it. If you’re using aggressive light levels, a lower red spectrum will buy you room before that becomes a problem, leaving you almost no photosynthetic punch to get it.

Far Red: More than Emerson
Far-red (700-750 nm) appears in more devices every year. It contributes little to photosynthesis on its own, but it moves plant morphology and works with red through the Emerson Enhancement Effect. Used properly, it helps to deepen the light, encourage uniformity of the canopy and encourage the response of the bloom. The key word is small. A touch of far red rounds out a spectrum; he’s not there to make a show.

Matching the red percentage with the room
Cannabis addresses the entire spectrum, not a line on a spec sheet. Reds cause flowers, but blues, greens and crimsons give the plant something it needs. Where you land in red refers to how you grow.

A lower red spectrum (30-40%) captures more blue and green, gives you better morphology, reduces the risk of photobleaching, and holds up when you’re running extreme PPFD. Moderate spectrum (40-55%) is the sweet spot in commercial greenhouses: strong photosynthetic efficiency, strong flowering, balanced growth. A high-red spectrum (70%+) makes the most sense in a greenhouse, where the sun is already giving you lots of blue and green and your supplemental light can cast effective red to fill the gap.

Where does the ETS MAX series fit in?
This is the thinking behind the JumpLights ETS MAX series. Instead of forcing a spectrum into each room, it rarely comes up because a greenhouse and a high PPFD indoor flower room are not the same problem.

  • ETS MAX 4C41% red: for indoor rooms operating at very high intensity, where photobleaching is a real risk. The wider, red bottom balance allows you to push the tops without overcooking them
  • ETS MAX 4A48% red: balanced internal spectrum that maintains high output while controlling bleaching.
  • ETS MAX 5B57% Red: A high-performance indoor option. Moderate red, marked with efficiency and flower at the same time, up to 3,450 μmol/s, with efficiency that holds the spectrum.
  • ETS MAX 7A76% red: built for the greenhouse. The sun already supplies blue and green, so this leans heavily on the complementary red, up to 3,900 μmol/s in the infrastructure most greenhouses already have in place.

Bottom line
Choosing an activity is not a competition for the highest red number. The winning spectrum is the one that matches your environment, your intensity, your genetics, and what you’re trying to produce. Combine spectrum, intensity, environmental control, light distribution and genetics, and you’ve got a lighting strategy. Keep a spec isolated and all you’ve got is a bright room.

The ETS MAX line was created around this idea: choose the spectrum of the room you actually have, indoor or greenhouse, and let the device work with your grow rather than against it.

For more information:
JumpLights
www.jumplights.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media